ADC Reviews

Osimertinib resistance study


Targeted drugs are the most eye-catching progress in lung cancer treatment in recent years, which have significantly improved the prognosis of patients with advanced lung cancer. Osimertinib is a representative drug of the third generation of targeted drugs, but such drugs also face the dilemma of drug resistance. So what should we do when third-generation targeted drugs such as osimertinib become resistant?

The drug resistance mechanism of osimertinib is very complex, and it can be divided into dozens of three categories. This complex drug resistance mechanism makes it difficult to achieve a package solution. A 2022 WCLC study showed that there is a common The most common drug resistance gene mutation (C797X). In the future, this gene mutation is expected to be a breakthrough to develop more practical replacement drugs for osimertinib resistance.

However, the above studies only provide a hope for addressing osimertinib resistance. So is there any way to use it now?
Another study found that in osimertinib-resistant lung cancer patients, a drug called “Xiaoyi” (evantuzumab, Amivantamab) combined with targeted and chemotherapy had an effective rate of 80%. And it is equally effective in patients with brain metastases. In addition, for osimertinib-resistant patients, some patients also achieved tumor shrinkage after the addition of “Xiaodu” (nexitozumab) and another monoclonal antibody.
Fourth-generation targeted drugs are also the focus of the report at the 2022 World Conference on Lung Cancer. Both JIN-A20 and BBT-176 have shown promising application prospects in animal models and clinical patients, and are expected to provide more treatment opportunities for osimertinib-resistant patients.

It should be reminded that the above research is still in the experimental stage, and there is still a long time distance between the large-scale clinical application.